Please use this identifier to cite or link to this item:
Title: Metformin revisited : an ‘old’ drug with a ‘new’ beginning
Authors: Vella, Sandro
Keywords: Metformin -- Therapeutic use
Non-insulin-dependent diabetes -- Disease management
Diabetes -- Disease management
Metformin -- Metabolism
Issue Date: 2013
Publisher: Malta College of Pharmacy Practice
Citation: Vella, S. (2013). Metformin revisited : an ‘old’ drug with a ‘new’ beginning. Journal of the Malta College of Pharmacy Practice, 19, 12-15.
Abstract: Acting as a weak activator of AMP-activated protein kinase, metformin has established itself as a cost-effective first line agent in the management of type 2 diabetes (T2DM). Besides slowing progression to this condition, its use is associated with improved survival and lower rates of myocardial infarction in T2DM, as well as benefits in stable patients with heart failure. Metformin may play a valuable role in early nephropathy, non-alcoholic fatty liver disease and as adjunct therapy in type 1 diabetes. It is increasingly advocated in patients with gestational diabetes and polycystic ovary syndrome. Its role as an anti-cancer agent remains controversial.
Appears in Collections:JMCPP, Issue 19
JMCPP, Issue 19

Files in This Item:
File Description SizeFormat 
2013-19-3.pdfMetformin revisited : an ‘old’ drug with a ‘new’ beginning573.5 kBAdobe PDFView/Open

Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.